Please login to the form below

Not currently logged in
Email:
Password:

vilanterol

This page shows the latest vilanterol news and features for those working in and with pharma, biotech and healthcare.

AZ’s COPD triple data sets up market clash with GSK

AZ’s COPD triple data sets up market clash with GSK

on LABA vilanterol, LAMA  umeclidinium and ICS fluticasone furoate - in the US and Europe last year.

Latest news

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    The EU regulator cleared Trelegy (fluticasone furoate/umeclidinium/vilanterol) - considered to be the most important new product in the company’s ailing respiratory franchise - as a maintenance treatment in adults with ... GSK has been bringing other

  • CDC backs GSK’s Shingrix over Merck & Co’s Zostavax CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

    Nucala itself saw sales more than double to £91m, but the approval of new triple therapy Trelegy (fluticasone furoate/umeclidinium/vilanterol) - billed as another key growth driver - came too late in

  • With US approval, GSK now needs rapid uptake for COPD triple With US approval, GSK now needs rapid uptake for COPD triple

    The FDA approved Trelegy (fluticasone furoate/umeclidinium/vilanterol) for the long-term, once-daily maintenance treatment of COPD patients who suffer breakthrough exacerbations despite being treated with two-drug combinations. ... Specifically, Trelegy

  • GSK closes in on EU approval for triple COPD therapy GSK closes in on EU approval for triple COPD therapy

    The EMA's advisory committee gave its blessing for Trelegy/Elebrato (fluticasone furoate, umeclidinium and vilanterol) as a maintenance therapy for COPD patients who do not respond to two-drug therapy ... product, now facing sales declines because of

  • GSK preps COPD filing for asthma pioneer Nucala GSK preps COPD filing for asthma pioneer Nucala

    agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium – and shingles vaccine Shingrix which is up for an FDA advisory committee meeting later today.

More from news
Approximately 10 fully matching, plus 58 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics